Racial equity in renal transplantation. The disparate impact of HLA-based allocation.

KIDNEY transplantation from either a living related or cadaveric donor is optimal treatment for most patients with end-stage renal disease (ESRD). 1 However, due to a critical shortage of organ donors, while more than 23 000 Americans await a suitable cadaveric kidney, fewer than 8000 receive transplants each year. 2,3 Approximately one third of ESRD patients in this country are African American (black), a proportion threefold greater than the representation of this racial group in the general population (12%). 1 Recently, the Inspector General reported that blacks are less likely than whites to receive a transplant, with almost double the waiting time. 4 Currently, cadaveric kidneys are allocated according to a federally mandated system based on quality of HLA matching. This policy is based on evidence that antigenic similarity between donor and recipient may enhance cadaveric graft survival and should be the primary factor influencing distribution. 5 Gjertson and colleagues

[1]  R. Evans.  The demand for transplantation in the United States. , 1990, Clinical transplants.

[2]  J. Alexander,et al.  Local use of kidneys with poor HLA matches is as good as shared use with good matches in the cyclosporine era: an analysis at one and two years. , 1987, Transplantation proceedings.

[3]  B. Julian,et al.  Influence of race on renal allograft survival in the pre- and postcyclosporine era. , 1987, Clinical transplants.

[4]  S. Takemoto,et al.  Report on 604 six-antigen-matched transplants. , 1990, Clinical transplants.

[5]  The use of race in medical research. , 1992, JAMA.

[6]  S. Takemoto,et al.  A comparison of kidney transplant survival in white and black recipients. , 1989, Transplantation proceedings.

[7]  N. Kutner,et al.  Quality of life of patients with end-stage renal disease. , 1985, The New England journal of medicine.

[8]  L. Hunsicker,et al.  The role of HLA matching for cadaveric renal transplants in the cyclosporine era. , 1992, Seminars in nephrology.

[9]  A. Okun,et al.  Equality and efficiency, the big tradeoff , 1975 .

[10]  K. Hanna.  Origins of the Medicare Kidney Disease Entitlement: The Social Security Amendments of 1972 , 1991 .

[11]  B. Julian,et al.  RENAL RETRANSPLANTATION: THE ROLE OF RACE, QUADRUPLE IMMUNOSUPPRESSION, AND THE FLOW CYTOMETRY CROSS‐MATCH , 1994, Transplantation.

[12]  E. Milford,et al.  Will transplant immunogenetics lead to better graft survival in blacks? Racial variability in the accuracy of tissue typing for organ donation: the fourth American workshop. , 1987, Transplantation proceedings.

[13]  W. McClellan,et al.  Race and sex differences in the identification of candidates for renal transplantation. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  B. Kahan,et al.  Low-dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. , 1993, Transplantation.

[15]  E. Reed,et al.  INFLUENCE OF RACE ON THE PREDICTABILITY OF MIXED LYMPHOCYTE CULTURE IDENTITY BY HLA‐DR MATCHING , 1983, Transplantation.

[16]  V. Lazda,et al.  Is allocation of kidneys on basis of HLA match equitable in multiracial populations? , 1989, Transplantation proceedings.

[17]  G. Danovitch,et al.  The effect of race on access and outcome in transplantation. , 1991, The New England journal of medicine.

[18]  J. Cecka,et al.  The race effect. , 1989, Clinical transplants.

[19]  A. Macleod,et al.  FK 506: an immunosuppressant for the 1990s? , 1991, The Lancet.

[20]  H. Ward,et al.  The beneficial effect of blood transfusion and the DR 1 gene dose on renal transplant outcome in blacks. , 1991, Transplantation.

[21]  Goust Jm,et al.  Major histocompatibility complex. , 1990 .

[22]  J. Cicciarelli,et al.  HLA matching: univariate and multivariate analyses of UNOS Registry data. , 1991, Clinical transplants.

[23]  P. Eggers,et al.  Effect of transplantation on the Medicare end-stage renal disease program. , 1988, The New England journal of medicine.

[24]  B. Julian,et al.  IMPROVED SURVIVAL OF PRIMARY CADAVERIC RENAL ALLOGRAFTS IN BLACKS WITH QUADRUPLE IMMUNOSUPPRESSION1 , 1992, Transplantation.

[25]  V. Lazda.  An evaluation of a local variance of the United Network for Organ Sharing (UNOS) point system on the distribution of cadaver kidneys to waiting minority recipients. Medical Advisory Committee, the Regional Organ Bank of Illinois. , 1991, Transplantation proceedings.

[26]  M. R. Mickey,et al.  Recipient pool sizes for prioritized HLA matching. , 1989, Transplantation.

[27]  R. Wolfe,et al.  The impact of nonidentical ABO cadaveric renal transplantation on waiting times and graft survival. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  P. Whelton,et al.  End-stage renal disease in US minority groups. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  V. Lazda.  The impact of HLA frequency differences in races on the access to optimally HLA-matched cadaver renal transplants. The Medical Advisory Committee. , 1992, Transplantation.

[30]  S Takemoto,et al.  National allocation of cadaveric kidneys by HLA matching. Projected effect on outcome and costs. , 1991, The New England journal of medicine.

[31]  G. Opelz,et al.  Kidney graft survival rates in black cyclosporine-treated recipients. Collaborative Transplant Study. , 1989, Transplantation proceedings.

[32]  D. Butkus.  Primary renal cadaveric allograft survival in blacks—Is there still a significant difference? , 1991 .

[33]  R. Colvin,et al.  A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. , 1993, Transplantation.

[34]  W K Vaughn,et al.  Factors affecting the waiting time of cadaveric kidney transplant candidates in the United States. , 1992, JAMA.

[35]  H. Sollinger,et al.  RS‐61443—A PHASE I CLINICAL TRIAL AND PILOT RESCUE STUDY 1 , 1992, Transplantation.

[36]  W. Braun.  Every kidney counts. , 1992, The New England journal of medicine.

[37]  D. Gjertson,et al.  HLA matching: a comparison of conventional and molecular approaches. , 1992, Clinical transplants.

[38]  P. Terasaki,et al.  The UNOS Scientific Renal Transplant Registry--1990. , 1990, Clinical transplants.

[39]  D. Gjertson,et al.  Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. The UNOS Scientific Renal Transplant Registry. , 1992, The New England journal of medicine.

[40]  T. Starzl,et al.  Biopharmaceutical aspects of FK-506. , 1987, Transplantation proceedings.

[41]  B. Julian,et al.  The impact of the UNOS mandatory sharing policy on recipients of the black and white races--experience at a single renal transplant center. , 1992, Transplantation.

[42]  Evans Rw.  The demand for transplantation in the United States. , 1990 .

[43]  D. Dunn,et al.  Long-term outlook for renal transplant recipients with one-year function. "Doctor, what are my chances"? , 1991, Transplantation.

[44]  T E Starzl,et al.  A multifactorial system for equitable selection of cadaver kidney recipients. , 1987, JAMA.